P1 receptors and cytokine secretion by Abbracchio, Maria P. & Ceruti, Stefania
REVIEW
P1 receptors and cytokine secretion
Maria P. Abbracchio & Stefania Ceruti
Received: 20 March 2006 /Accepted: 10 April 2006 / Published online: 30 January 2007
# Springer Science + Business Media B.V. 2007
Abstract Evidence has accumulated in the last three
decades to suggest tissue protection and regeneration by
adenosine in multiple different cell types. Adenosine
produced in hypoxic or inflamed environments reduces
tissue injury and promotes repair by receptor-mediated
mechanisms. Among other actions, regulation of cytokine
production and secretion by immune cells, astrocytes and
microglia (the brain immunocytes) has emerged as a main
mechanism at the basis of adenosine effects in diseases
characterized by a marked inflammatory component. Many
recent studies have highlighted that signalling through A1
and A2A adenosine receptors can powerfully prevent the
release of pro-inflammatory cytokines, thus inhibiting
inflammation and reperfusion injury. However, the activa-
tion of adenosine receptors is not invariably protective of
tissues, as signalling through the A2B adenosine receptor
has been linked to pro-inflammatory actions which are, at
least in part, mediated by increased release of pro-
inflammatory cytokines from epithelial cells, astrocytes
and fibroblasts. Here, we discuss the multiple actions of P1
receptors on cytokine secretion, by analyzing, in particular,
the role of the various adenosine receptor subtypes, the
complex reciprocal interplay between the adenosine and the
cytokine systems, their pathophysiological significance and
the potential of adenosine receptor ligands as new anti-
inflammatory agents.
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Abbreviations
ACTH adrenocorticotropic hormone
ADA adenosine deaminase
CGS15493 9-chloro-2-(2-furyl)[1,2,4]triazolo[1,5-c]
quinazolin-5-amine
CHF chronic heart failure
COPD chronic obstructive pulmonary disease
COX-2 cyclooxygenase-2
GH growth hormone
IFNg interferon gamma
IL interleukin
Ins(1,4,5)P3 inositol(1,4,5)-trisphosphate
IPDX 3-isobutyl-8-pyrrolidinoxanthine
LPS lipopolysaccharide
MCP-1 monocyte chemotactic protein-1
NOS nitric oxide synthase
PBMC peripheral blood mononuclear cells
PG prostaglandin
PRL prolactin
SCH58261 5-amino-7-(2-phenylethyl)-2-(2-furyl)
pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]
pyrimidine
Th1/2 type 1/2 helper lymphocytes
TNFa tumour necrosis factor alpha
VEGF vascular endothelial growth factor
ZM241385 4-(2-[7-amino-2-(2-furyl)(1,2,4)triazolo
(2,3-a)(1,3,5)triazin-5-yl amino]ethyl)phenol
Introduction
Adenosine acts as a local mediator with generally cytopro-
tective functions in mammalian organisms. These actions
are mediated by the activation of four distinct adenosine re-
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receptors—which are all members of the G protein-coupled
receptor (GPCR) superfamily and each of which has a
unique tissue distribution, pharmacological profile and
effector coupling (not reviewed here; for a recent seminal
review, the reader is referred to Jacobson and Gao [1]).
As elegantly reviewed by Linden [2], adenosine pro-
motes tissue protection and repair through four general
modes of action: increased oxygen supply/demand ratio,
preconditioning, anti-inflammatory effects and stimulation
of angiogenesis. Thus, adenosine downregulation of in-
flammatory and immune responses in injured tissues plays
a crucial role in the beneficial effects induced by this
nucleoside. In recent years, the elucidation of the molecular
mechanisms at the basis of these actions has revealed that
they occur, at least in part, through modulation of the
production and release of pro-inflammatory cytokines.
Here, we review some of the most compelling evidence
on the roles of the various adenosine receptor subtypes in
cytokine secretion, with major focus on the direct effects
of adenosine on cytokine production and release by
immune cells, by astrocytes and by microglia, the brain
immunocytes. Due to the obvious involvement of
immune cells in inflammatory diseases of the respiratory
and cardiovascular systems, we also discuss modulation
of cytokine secretion by adenosine in asthma and chronic
heart failure.
Adenosine modulation of cytokine secretion in immune
cells: is adenosine the danger sensor that stops
the immune response?
The first demonstrations of the immunosuppressive effects
mediated by intracellular cyclic adenosine monophosphate
(cAMP) and extracellular adenosine date back to the 1970s
[3, 4]. Since then, detailed studies on the pharmacological
effects of adenosine [5, 6] and on the involvement of
specific adenosine receptor subtypes ([7, 8]; see also below)
have expanded those original descriptions to cells of both
the innate and adaptive immune systems, highlighting
adenosine as a critical player in the physiological mecha-
nisms that downregulate activated immune cells and protect
tissues from inflammatory damage (for seminal and
comprehensive reviews, see Sitkovsky et al. [9]a n d
Sitkovsky and Ohta [10]).
It is known that immune cell-mediated destruction of
pathogens may result in excessive collateral damage to
normal tissue and that the failure to control activated
immune cells and to downregulate acute inflammatory
responses may cause immunopathologies and chronic
inflammatory diseases. It is believed that regulation of the
immune system requires at least two ‘danger’ signals
(elegantly reviewed in Sitkovsky and Ohta [10]). The first
danger signal indicates the presence of pathogens, injury or
mutations resulting in the death or scavenging of cells
(reviewed by Matzinger [11]). As a result of this danger
signal, immune cells are activated to initiate immune
responses: they kill pathogens by cytokines, reactive
oxygen and nitrogen species and cellular cytotoxicity, and
expand inflammation by attracting and activating many
other effector cells through the release of pro-inflammatory
cytokines and chemokines. However, uncontrolled expan-
sion of inflammatory responses might cause tissue damage
and loss of function: this is at the basis of the critical
dichotomy of inflammation, which is often described as a
‘double-edged sword’ [12]. Inflammation and immune
reactions are indeed believed to start as time- and site-
specific defense mechanisms. Failure to resolve an acute
beneficial response could later lead to a vicious and anar-
chic state of chronic activation, which causes healthy tissue
damage. To avoid excessive collateral tissue damage,
therefore, the tissue may release a second danger signal
that can evoke anti-inflammatory responses. This second
danger signal indicates the danger from overactive immune
cells and would trigger the downregulation of the pro-
inflammatory activities of the immune system to prevent
destruction of healthy tissues. As underlined by Sitkovsky
and Ohta [10], the final outcome will be determined by a
balance between the first pro-inflammatory danger signal
and the second anti-inflammatory signal. The mechanisms
that are triggered by the second danger signal are related to
the extent of change to tissue microenvironment and are
timed with a high level of precision, so that immune cells
keep the ability to destroy remaining pathogens but with
much less damage to healthy cells. Sitkovsky and Ohta [10]
observed that the least tolerated damage during an immune
response is damage to the structures of the microcirculation,
which would cause an interruption of the local blood
supply. On this basis, they proposed local tissue hypoxia as
the primary event indicating the need to stop overactive
immune cells and adenosine as a key “OFF” signal
mediating downregulation of immune cell activity. Even
short periods of hypoxia are indeed known to strongly
elevate adenosine levels as a result, on the one side, of rapid
breakdown of ATP, and, on the other side, of hypoxia-
induced inhibition of adenosine kinase, which, under
normal conditions, rephosphorylates the nucleoside to
AMP. Hypoxia, such as that associated with brain ischae-
mia, also results in upregulation of adenine nucleotide
metabolizing ectoenzymes, which may lead to an even
more enhanced production of adenosine. Interestingly, such
an upregulation has been demonstrated to occur in vivo
upon induction of middle cerebral artery occlusion in
rodents as a result of brain ischaemia [13].
14 Purinergic Signalling (2007) 3:13–25Among known adenosine receptors, A2 receptors have
properties that make them particularly well suited to serve
as sensors of pro-inflammatory activities and to act as stop
signals of overstimulated immune cells. First of all, both
A2A and A2B receptors are coupled to Gs proteins and to
increases of intracellular cAMP, which is in line with the
prime importance of cAMP elevation in inhibition of
immune cell activity (in this respect, see also Raskovalova
et al. [14]) (Fig. 1). Interestingly, the A2A receptor has high
affinity and the A2B receptor has low affinity for adenosine,
suggesting that they could be recruited sequentially,
depending upon the extent of adenosine accumulation at
the site of inflammation, and, thus, upon the degree of
hypoxia. This would allow a graded escalation of the
Fig. 1 Role of A2 adenosine receptors in delayed negative feedback
downregulation of activated immune cells in inflammation. a Patho-
gens, virus-infected, mutated or otherwise injured cells activate
resident, recruited or tissue-surveying immune cells inducing them to
produce pro-inflammatory molecules (e.g. cytokines, reactive oxygen
species). b This leads to pathogen destruction and, as a result of strong
activation, some non-infected, ‘innocent’ bystander cells in collateral
tissue can also be damaged. c According to the hypothesis raised by
Sitkovsky and Ohta [10], it is the collateral damage to the microvas-
culature owing to the continuing production of inflammatory molecules
that is of crucial significance in signalling the extent of tissue damage.
In particular, increased damage to microvasculature may result in the
interruption of blood supply and low oxygen tension (hypoxia) in
the most damaged microenvironment. d Local tissue hypoxia leads to
the accumulation of extracellular adenosine (Ado), as a result of both
hypoxia-associated decrease in intracellular levels of ATP and
inhibition of adenosine kinase (see text). e As the oxygen tension falls
further, the concentrations of extracellular adenosine ([Ado]ext) will
increase and this, in turn, will determine the intensity of signalling
through sequential recruitment of high-affinity (A2A) and low-affinity
(A2B) adenosine receptors. f The sufficiently high extracellular
adenosine levels will trigger the maximal activation of Gs protein-
coupled A2A and A2B adenosine receptors and the accumulation of
intracellular cAMP, which has strong immunosuppressive properties.
g The increased cAMP then strongly inhibits ongoing effector functions
and prevents their triggering in the newly activated immune cells that
have just arrived in the inflamed area. Immune cells also express Gi
protein-coupled A1 and A3 receptors, which inhibit adenylyl cyclase
and cAMP formation, which, in turn, would provide another level of
control to prevent the premature inhibition of immune cells by A2
receptors. h This delayed negative feedback mechanism might provide
immune cells sufficient time to destroy the pathogen but also prevents
additional collateral tissue damage by inhibiting the production of pro-
inflammatory cytokines and cytotoxic molecules. Reprinted and
modified from Sitkovsky and Ohta [10], copyright 2005 with
permission from Elsevier
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circumstances, inhibition of immune cells only partially
without completely stopping pathogen destruction. In this
context, site- and time-specific actions of adenosine would
also be favoured by its short half-life in vivo, which make
this nucleoside act in an autocrine or paracrine manner as a
local “metabokine” (see Sitkovsky and Ohta [10] and
references therein). Globally, this would assure the local
inhibition of immune cells in the most injured and therefore
adenosine-rich areas, while permitting ongoing pathogen
destruction in neighbouring areas. It is interesting to
underline that adenosine signalling via Gs protein-coupled
A2A and A2B receptors can be counteracted by Gi protein-
coupled A1 and A3 receptors. Virtually all immune cells
express both A1 and A2 receptors, which would on the one
side assure that no immune cell can escape inhibitory
signalling by adenosine, but, on the other side, would
provide another level of control to prevent the premature
inhibition of immune cells by A2 receptors. In line with this
hypothesis, Gi protein-coupled versus Gs protein-coupled
adenosine receptors do have opposite effects on the same
neutrophil function (ibidem). Moreover, it seems that,
besides inhibiting inflammatory processes, A2 receptors
also have the capacity to redirect the effector class of the
immune response and change the patterns of cytokine and
chemokine secretion by activated immune cells [15]. By
activating A2 receptors, adenosine can inhibit tumour
necrosis factor alpha (TNFa), interleukin-12 (IL-12) and
chemokine CXCL10 production, enhance the secretion of
IL-10 and augment the release of the chemokine CCL17.
Thus, activation of adenosine A2 receptors might diminish
the capacity of dendritic antigen-presenting cells to initiate
and amplify type 1 T-helper (Th1) lymphocyte immune
responses and therefore shift the Th1 versus the type 2 T-
helper (Th2) lymphocyte balance (ibidem).
The generation of adenosine receptor gene-deficient
mouse models has firmly established a unique role of A2
adenosine receptors in several models of acute inflamma-
tion and of tissue injury [9, 10, 16, 17]. A2A adenosine
receptor-deficient mice showed dramatically increased local
tissue damage and prolonged presence of pro-inflammatory
cytokines, such as TNFa, interferon gamma (IFNg) and IL-
12, with respect to wild-type animals. Subthreshold doses
of inflammatory stimuli, which do not cause liver injury in
wild-type mice, induced extensive liver damage and
elevated levels of cytokines in knockout mice. In line with
these data, similar effects were observed upon injection of
the A2A receptor antagonist ZM241385 into wild-type
mice, which developed severe tissue damage in response
to subthreshold doses of inflammatory stimuli. These data
strongly suggest an in vivo role of A2A adenosine receptors
in the regulation of inflammation and support the hypoth-
esis that this mechanism is non-redundant because of the
failure of other anti-inflammatory mechanisms to compen-
sate for the absence of A2A adenosine receptors.
Adenosine modulation of cytokine release in the lung:
a key role in asthma
Inflammation plays a major role in both the development
and progression of lung diseases, such as asthma and
chronic obstructive pulmonary disease (COPD). Following
a chemical, environmental, mechanical or antigenic injury
to the lung tissue, the release of various cytokines and
chemokines is initially aimed at sustaining the repair
process, but its deregulation and persistence later contribute
to tissue destruction and remodelling [18].
Multiple cell types are recruited at the site of lung
inflammation, including eosinophils, neutrophils, lympho-
cytes, macrophages and mast cells, and they represent the
major sources of inflammatory mediators. In allergic
asthma, a prominent role is played by Th2 lymphocytes
which release various cytokines (e.g. IL-4, IL-5, IL-13 and
IL-9; [19]) contributing to eosinophilia, IgE production,
airway hyperreactivity and mucus hypersecretion. In all
asthmatic conditions, pulmonary mast cells represent major
players of the inflammatory reaction, since, following acute
exposure to allergens, pollutants or other chemical stimuli,
they degranulate releasing a huge variety of autacoids,
including prostaglandin D2, cytokines, cysteinyl leuko-
trienes, enzymes and histamine [20]. These chemical
entities contribute to the development of the acute asthmatic
attack, modulating bronchoconstriction, but also play an
important role in the chronic development of the disease. In
fact, mast cells have been implicated in airway remodelling
[20] and are currently believed to be primarily responsible
for the development of airway hyperreactivity (a character-
istic feature of chronic asthma in which airways react in an
exaggerated way to exposure to mild insults; [21]). During
the chronic phase of asthma, lung fibroblasts, epithelial
cells and smooth muscle cells further contribute both to the
evolution of the disease and to airway remodelling [18].
We have previously mentioned that adenosine concen-
trations rapidly increase in hypoxic and inflamed tissues,
due to ATP breakdown. Thus, it was anticipated that high
adenosine concentrations could be found also in the lung of
asthmatic patients and that the nucleoside might contribute
to the disease. The first indication of a possible role for
adenosine in mediating bronchoconstriction dates back to
the 1980s when Cushley and co-workers demonstrated that
inhaled adenosine was ineffective on normal, but was a
potent bronchoconstrictor of asthmatic airways [22]. These
results were confirmed a few years later also in patients
with chronic obstructive pulmonary disease, by utilizing
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bronchoconstrictant [23].
From the very beginning, it was hypothesized that
adenosine was not acting directly on bronchial smooth
muscle cells, but exerted its bronchoconstrictant activity
through an indirect mechanism, involving mast cell
degranulation. This hypothesis was later confirmed by the
ability of histamine H1 and cysteinyl leukotriene receptor
1-selective antagonists as well as cyclooxygenase 1 and 2
inhibitors and mast cell stabilizing drugs (i.e. sodium
cromoglicate) to effectively counteract the effects of
inhaled AMP [24]. Indeed, high histamine plasma concen-
trations were detected in asthmatic patients after AMP
inhalation, due to mast cell degranulation accompanied by a
r a p i da i r w a yn a r r o w i n g[ 25]. The selective effect of
adenosine in asthmatic subjects has recently opened up
the opportunity to develop a diagnostic test based on
adenosine or AMP inhalation challenge [26] which could
effectively discriminate between asthmatic and patients
affected by COPD. In fact, adenosine-mediated broncho-
constriction is highly enhanced when the allergic compo-
nent is relevant, like in asthma, but is lower in the case of
COPD [27]. AMP inhalation might also be used to monitor
the efficacy of the corticosteroid therapy [27]. Anyway,
despite the importance of such a diagnostic test, its use
should be carefully evaluated due to the development of an
inflammatory response after AMP inhalation that could
have problematic outcomes [28]. The important role played
by adenosine in modulating allergic response has been very
recently further highlighted in ragweed-sensitized mice
where adenosine inhalation increased infiltration of inflam-
matory cells and the appearance of markers of inflammation
(such as eotaxin) in the bronchoalveolar lavage [29].
Several studies have demonstrated that adenosine effects
are mediated by activation of its surface receptors, but
important differences among species have been observed.
In fact, with the discovery and cloning of the A3 adenosine
receptor subtype, its prominent role in modulating mast cell
degranulation was described in rodents. The situation
appears to be different in human mast cells, where the
A2B adenosine receptor is the likely candidate for mediation
of the pro-inflammatory and bronchoconstrictant effects of
the nucleoside in asthmatic patients [18]. For instance, data
from HMC-1 cells (a human mast cell line) have shown that
activation of A2B receptors leads to IL-8 generation, which
can be attenuated by rather selective antagonists [30], and
to enhanced IL-4 and IL-13 secretion when cells are co-
cultured with human B cells [31]. Both the A3 and the A2B
subtypes are low-affinity receptors for adenosine and can
therefore be activated only when high levels of the
nucleoside are present, such as in chronic inflammatory
situations. The involvement of the low-affinity A2B
(coupled to both adenylyl cyclase and phospholipase C) in
the pro-inflammatory actions of adenosine could also
explain its selective action on asthmatic subjects. In fact,
under physiological conditions, low adenosine concentra-
tions activate the high-affinity A2A receptor subtype
localized on mast cells and coupled to increases in
intracellular cAMP concentrations which, in turn, inhibit
histamine release [27] (Fig. 2). Conversely, upon chronic
inflammation, high adenosine levels are reached leading to
activation of the A2B subtype which may, in turn, promote
histamine release by raising inositol(1,4,5)-trisphosphate
[Ins(1,4,5)P3] concentrations [27] (Fig. 2).
The discovery of the role of the A2B adenosine receptor
in promoting lung inflammation has also helped to clarify
the mechanism of action of a well-known anti-asthmatic
agent, such as theophylline, which has been used in therapy
for over 50 years [32]. Theophylline is known as both a
phosphodiesterase inhibitor and an antagonist at adenosine
receptors, but its anti-asthmatic actions were mainly
ascribed to the former activity based on the fact that
enprofylline, another xanthine derivative, is as effective as
theophylline in treating asthma but bears a much lower
affinity for adenosine receptors [33]. The discovery that the
affinity of these two molecules at the A2B receptor is
similar and lies below the range of plasma concentrations
that are observed in therapy has further clarified the
important role played by this receptor subtype in both the
onset and development of lung inflammatory diseases [32].
Activation of the A2B adenosine receptor has been also
demonstrated to play an important role in the development
of airway hyperresponsiveness, contributing to the chronic
evolution of the disease, by modulating cytokine secretion
from various cell types. As previously mentioned, stimula-
tion of the A2B receptor on human mast cells results in the
engagement of Th2 lymphocytes which in turn release IL-4
and IL-13 [31]. IL-13 is involved in IgE synthesis from B
cells, leading to chronic inflammation, alveolar remodel-
ling, pulmonary fibrosis and mucus production [19].
Indeed, A2B stimulation on human lung fibroblasts induces
IL-6 release which autocrinally promotes their pathological
differentiation into myofibroblasts [34]. Upon adenosine
stimulation also bronchial smooth muscle cells release IL-6
and monocyte chemotactic protein-1 (MCP-1, also known
as CCL-2; [35]), another important mediator of disease
progression. Finally, it has been also demonstrated that aden-
osine canupregulatemucin gene expressionin human airway
epithelial cells [36]. Based on these observations, selective
A2B antagonists (such as IPDX, CGS15493 and CVT 6883;
[37, 38]) have been proposed as powerful and effective anti-
asthmatic drugs; some of them are currently in clinical trials
for the long-term treatment of lung diseases [32].
In very recent years, elegant studies from Blackburn and
co-workers have further highlighted the importance of high
adenosine concentrations in the development of lung
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mice [39]. The most relevant phenomenon observed in
these animals is the development of an “asthmatic”
inflammatory phenotype, accompanied by all the classic
symptoms and cellular changes observed in patients [40].
Indeed, the genetic removal of the A1 adenosine receptor
subtype further strengthened the asthmatic phenotype,
highlighting a protective or modulatory role for this
receptor subtype against the development of lung inflam-
mation in ADA-deficient mice which might have a
functional counterpart also in humans [41].
Finally, a protective role has been also demonstrated for
the A2A subtype (see also above). Its activation, in fact,
suppresses activation and degranulation of neutrophils,
mast cells, monocytes and T lymphocytes [27, 32, 42],
thus envisaging the possible use of selective A2A agonists
as therapeutic agents.
Adenosine modulation of cytokine release in the brain:
beyond its role as a retaliatory neuroprotective
metabolite
More than 20 years ago, a seminal paper from Newby
introduced the concept of “retaliatory metabolite” to
recapitulate the protective adenosine functions in brain
and heart ischaemic tissues [43]. An increasing amount of
details on adenosine functions have subsequently come
from the work of several groups in this field, and very
recent observations suggest the situation not to be so well-
defined as it seemed at the beginning.
It was already known that following ischaemic and/or
traumatic injury or under inflammatory situations extracel-
lular adenosine concentrations increase several fold over
basal levels due to the rapid breakdown of ATP [44]. This is
particularly true in the central nervous system, where ATP
Fig. 2 Role of A2 adenosine
receptors in the modulation of
the release of histamine in the
lung under physiological or
pathological conditions. Both
high-affinity A2A and low-affin-
ity A2B adenosine receptors are
positively coupled to cAMP
production through Gs. In addi-
tion, the A2B subtype can also
promote Ins(1,4,5)P3 production
via Gq activation. Under normal
conditions a, low extracellular
adenosine concentrations acti-
vate the A2A receptor subtype,
leading to the increase of intra-
cellular cAMP concentrations,
which are known to inhibit
histamine release. In asthma and
COPD, high extracellular aden-
osine concentrations are reached
b. This in turn might lead to the
downregulation of high-affinity
A2A receptors and might there-
fore increase the relative impor-
tance of the low-affinity A2B
subtype. The concomitant re-
duction in cAMP concentra-
tions, paralleled by
overproduction of Ins(1,4,5)P3
through Gq activation, will pro-
mote histamine release as the
final outcome, thus contributing
to the development and exacer-
bation of the disease. Reprinted
from Spicuzza et al. [27], copy-
right 2003 with permission from
Elsevier
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with excitatory neurotransmitters [45], and adenine nucleo-
tides derive from damaged or dying cells undergoing nucleic
acid degradation. Ectonucleotides rapidly degrade nucleo-
tides to adenosine, whose concentration rises from the
nanomolar range under basal condition to 10-50 μMf o l l o w -
ing ischaemia [46]. The neuroprotective actions of adenosine
have been known for several years and have been mainly
associated with activation of the presynaptic A1 receptor sub-
type leading to decreases of neuronal firing and of excitatory
neurotransmitter release [47]. Acting on postsynaptic A1
receptors, adenosine is also able to hyperpolarize plasma
membranes, thus reducing the propagation of excitatory stim-
uli. On the contrary, the role of the A2A adenosine receptor
subtype is controversial. Under some experimental para-
digms, activation of A2A receptors leads to neuroprotection;
however, induction of neuronal death has also been
proposed, since A2A receptor antagonists are neuroprotective
in several experimental models of neurodegeneration [48].
Not only neurons, but also glial cells (i.e. astrocytes and
microglia) express all the four cloned adenosine receptor
subtypes, with the exception of the A2B receptors that have
not been found in microglia. In recent years, the discovery
of the important role of glial cells in controlling brain
response to traumatic injury has opened up the possibility
that some of the effects mediated by adenosine in the brain
may also depend on its ability to modulate glial cell functions.
Astrocytes and microglia react rapidly to noxious stimuli
by increasing their proliferation rate, leading to the
formation of an astrocytic scar isolating damaged neurons
(the so-called reactive astrogliosis) and to the recruitment of
microglial cells at the site of injury [49]. Adenosine exerts a
double action on the proliferation of glial cells, with the A1
and the A2A receptor subtype reducing and enhancing
astrocyte proliferation, respectively [46]. The effect on
microglial cell proliferation is less clear and depends upon
the cellular environment and the receptor subtypes that are
expressed in any given experimental model [50, 51].
In the long term, glial cells contribute to brain remodel-
ling and to the final outcome of the traumatic event through
their ability to release both pro- and anti-inflammatory
cytokines [46]. Adenosine receptors have been demonstrat-
ed to modulate cytokine release from glial cells in different
ways. In astrocytes, the overall result of adenosine receptor
engagement is the development of an anti-inflammatory
phenotype. In fact, A1 receptor activation induced nerve
growth factor (NGF) release from astrocytes [52], whereas
A2B and the A3 receptor subtypes mediated increases of the
cytokines IL-6 and CCL2, respectively [53, 54]. Moreover,
A2A receptors play an important role in downregulating
nitric oxide synthase (NOS) following pro-inflammatory
stimuli, such lipopolysaccharide (LPS), IFNg or TNFa plus
IL-1β [55].
The role of adenosine in controlling cytokine release
from microglial cells appears to be more contradictory. So
far, no role for A1 receptors has been demonstrated,
whereas activation of the A2A receptor subtype seems to
drive the appearance of a pro-inflammatory phenotype,
with an upregulation of cyclooxygenase-2 (COX-2) expres-
sion, followed by increased prostaglandin E (PGE)2
synthesis [56], together with an augmented NO production
[57]. Nevertheless, an anti-inflammatory role for some
COX-2 products, such as PGD2 and PGJ2 has been recently
demonstrated [46]. Indeed, the recruitment of the microglial
A2A receptor has been also associated with an increase in
NGF production [58], thus suggesting that the final
outcome of adenosine receptor activation is probably
influenced by the cellular environment, as hypothesized
for microglial cell proliferation (see above). Studies on
human microglial cells have suggested that the A2A
receptor subtype is preferentially expressed by activated
microglia [59]. If confirmed, these observations might
contribute to depicting a scenario where the A2A receptor
subtype plays a neurodegenerative role upon pathologic
conditions. Finally, the role of the A3 adenosine receptor in
controlling microglial functions was unclear until very
recently, when its activation was demonstrated to promote
ERK1/2 phosphorylation [60] and to reduce LPS-induced
TNFa production through inhibition of the PI3-kinase/AKT
pathway [61]. The apparent contradiction in adenosine
modulation of microglial cell functions, with the develop-
ment of either a pro- or an anti-inflammatory phenotype, is
in agreement with the double-edged sword role exerted by
the inflammatory process, where failure to resolve an initial
beneficial inflammatory reaction leads to a delayed and
chronic detrimental situation ([12]; see also above). Thus,
different receptor subtypes might be recruited at different
times after the initial traumatic/inflammatory trigger, also
depending upon changes in adenosine concentrations over
time, contributing to the plasticity of brain response to
traumatic and ischaemic events.
An important contribution to the production of cytokines
and chemokines in the brain during ischaemia comes from
infiltrating blood immune cells. A specific section of this
review is dedicated to a detailed analysis of the role of
adenosine in modulating immune cell function. Concerning
the role of immune cell adenosine receptors in brain
pathologies, a potent protective role for the A1 receptor
subtype has been demonstrated in experimental allergic
encephalomyelitis, an animal model of multiple sclerosis
[62]. In fact, A1 adenosine receptor null mice develop a
severe form of the disease with respect to wild-type litter
mates, characterized by demyelination and oligodendrocyte
cytotoxicity evoked by pro-inflammatory molecules (main-
ly IL-1β and matrix metalloproteinase-12) produced by
macrophages [62]. This scenario recapitulates findings in
Purinergic Signalling (2007) 3:13–25 19multiple sclerosis patients, thus suggesting that modulation
of the A1 adenosine receptor subtype might represent a
novel pharmacological approach to currently incurable
demyelinating diseases.
Again, the role of the A2A receptor subtype expressed by
infiltrating cells in modulating brain damage appears
contradictory. In fact, inactivation of the A2A receptor of
bone marrow-derived cells has been demonstrated to
protect brain tissue from middle cerebral arterial occlusion
injury; this effect was accompanied by a parallel reduction
in the production of pro-inflammatory cytokines from
infiltrating macrophages [46], suggesting a detrimental role
for this receptor subtype during ischaemic brain damage
(see also above). On the contrary, the A2A receptor plays a
Fig. 3 In vitro induction of
reactive astrogliosis by the A2B
adenosine receptor in TNFa-
treated cells. Exposure of human
astrocytoma cells to TNFa
increases A2B receptor signal-
ling and G protein coupling by
reducing agonist-dependent re-
ceptor phosphorylation and de-
sensitization, without affecting
receptor protein and mRNA
levels (notshown;seeTrincavelli
et al. [68] for details). From a
functional point of view, these
biochemical changes translate
into the ability of the A2B re-
ceptor to induce elongation of
astrocytic processes, a typical
hallmark of reactive astrogliosis.
In fact, marked morphological
changes can be observed in cells
preincubated with 1,000 U/ml
TNFa for 24 h, and subsequent-
ly exposed to 1 μM NECA for
30 min, followed by an addi-
tional 72 h in drug-free medium
b, with respect to cultures ex-
posed to TNFa alone, which
induced no effect “per se”
a. Quantification of results indi-
cates a 25-30% elongation of
cell processes by NECA in the
presence of TNFa, with respect
to TNFa alone. No effect on
process elongation was detected
when cells were exposed to
NECA without TNFa pretreat-
ment (see Trincavelli et al. [68]
for details). NECA-induced as-
trocytic elongation can be com-
pletely inhibited by the
concomitant exposure to MRS
1706 10 nM, c, a selective A2B
antagonist, thus confirming a
specific involvement of this re-
ceptor subtype in the observed
effects. Magnification: ×32.
Scale bar: 30 μM. Reprinted
from Trincavelli et al. [68],
copyright 2004 with permission
from Blackwell Publishing
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of endotoxin-induced meningitis [46] and has been recently
demonstrated to prevent human immunodeficiency virus
(HIV)-1 Tat-induced production of TNFa by macrophages
[63]. Taken together, these observations further confirm an
anti-inflammatory and neuroprotective role played by the
A1 adenosine receptor subtype, whilst the role of the A2A
receptor in neurodegeneration might depend upon the
timing of the disease and the peculiar mechanisms at the
basis of its aetiopathology.
A key role for adenosine A1 and A3 receptor subtypes
has been also described in ischaemic preconditioning,
where a mild and transient ischaemic attack reduces the
susceptibility of brain tissue to a subsequent and prolonged
ischaemic episode. A role for adenosine in protection
against release of cytokines and cytotoxic molecules from
residential macrophages in ischaemic preconditioning of
the heart has been clearly demonstrated (for review, see
Picano and Abbracchio [64] and references therein). Given
the recent observation of an altered pattern of main
cytokine expression (in particular IL-1 and IL-6) in
ischaemic animals previously subjected to preconditioning
with respect to non-conditioned animals [65], a possible
role for adenosine receptors in modulating cytokine release
during the induction of cerebral ischaemic preconditioning
can also be foreseen.
Not only can adenosine influence cytokine expression
and release, but a tight cross-talk between cytokine and
growth factor networks and adenosine receptors can be
envisaged based on recent observations. In fact, exposure of
rat cortical astrocytes to IL-6 upregulates adenosine A1
receptor expression [66], and inhibition of the A2A receptor
subtype by the selective antagonist SCH58261 completely
prevented basic fibroblast growth factor (bFGF)-induced
reactive astrogliosis [67]. Moreover, TNFa increased A2B
adenosine receptor functional response and G-protein
coupling in astrocytes in vitro, without any changes in
receptor levels but by inhibiting receptor phosphorylation
and downregulation. The functional outcome was that
activation of this receptor subtype in human astrocytoma cells
induced reactive astrogliosis only in the presence of the pro-
inflammatory cytokine ([68]; Fig. 3). Taken together, these
results suggest that a highly complex interconnection among
adenosine signalling pathways, cytokines and growth factors
is involved in the generation of the final outcome in response
to ischaemic, traumatic and inflammatory events. The in-
depth knowledge of the various regulatory pathways might
open up new therapeutic strategies to both acute and chronic
neurodegenerative disorders.
Finally, increases in cytokine concentrations (in partic-
ular IL-6) are known to be potent signals for hormone
release by the pituitary gland [i.e. adrenocorticotropic
hormone (ACTH), growth hormone (GH), prolactin (PRL)
and gonadotrophin] [69]. Adenosine A2B receptors are
highly expressed by the folliculostellate cells of the anterior
pituitary, and their activation stimulates IL-6 and vascular
endothelial growth factor (VEGF) release [69]. Since
folliculostellate cells provide a cellular network integrating
both locally generated and systemic signals to modulate
hormone secretion, activation of the adenosine A2B receptor
may represent an important regulatory pathway in the
neuroimmune system [69]. A2B-mediated IL-6 and VEGF
production might also play an important role during the
development and growth of pituitary tumours, since it can
be envisaged that high adenosine concentrations are
achieved in the hypoxic core of the tumoural mass due to
ATP breakdown [69].
Adenosine modulation of cytokine production in the
heart: an efficient, although incomplete, mechanism
of protection against heart failure progression
Since the sentinel description by Levine and colleagues of
inflammatory cytokines in patients with heart failure in
1990 [70], there has been a growing interest in understand-
ing the role of these molecules in regulating cardiovascular
function under both physiological and pathological con-
ditions. In particular, data have been accumulated to
suggest that many aspects of heart failure can be explained
by the known biological effects of pro-inflammatory
cytokines such as TNFa, IL-1 and IL-6 [71]. When
expressed at sufficiently high concentrations, such as those
found in patients with chronic heart failure (CHF),
cytokines are sufficient to mimic several aspects of the so-
called heart failure phenotype, including progressive left
ventricular dysfunction, pulmonary oedema, left ventricular
remodelling, foetal gene expression and cardiomyopathy
[72, 73, 74]. In CHF patients, both cardiac myocytes, heart
residential macrophages and peripheral blood mononuclear
cells (PBMC) are able to produce great amounts of TNFa
and IL-6. Of these, TNFa represents a serious candidate as
a mediator of the myocardial dysfunction progression and
remodelling that are part of the natural history of CHF,
since it induces hypotension, decreases myocardial con-
tractility and ejection fraction and also exerts a direct
cytotoxic effect on cardiac myocytes [75, 76, 77]. All this
evidence supports the “cytokine hypothesis” [78] that heart
failure progresses, at least in part, as a result of the toxic
effects exerted on the heart and the peripheral circulation by
endogenous cytokine cascades. Of course, this does not
imply that cytokines cause heart failure “per se”, but rather
that the overexpression of cytokine cascades or, alterna-
tively, a dysfunction of the mechanisms and factors reg-
ulating theirsecretion(seealso below), contributestodisease
progression.
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factors that are capable of attenuating cytokine cascade in
CHF is beginning to be explored. In this respect, an ideal
system is represented by adenosine. This nucleoside has
well-known homeostatic activities in regulating myocardial
blood flow, release of catecholamines and, as more recently
demonstrated, of cytokines from inflammatory cells and has
been shown to reduce myocardial injury resulting from
periods of ischaemia (for review, see Villarreal et al. [79]).
The A2A receptor seems to be particularly important in
mediating these beneficial effects. Activation of this
receptor subtype on immune cells (e.g. monocytes and
lymphocytes) has long been known to mediate anti-
inflammatory responses, including inhibition of TNFa
release (see also above; for review see Sitkovsky et al.
[9]), which may have interesting implications for the
development of heart disease. In line with this hypothesis,
an increase of A2A adenosine receptor expression, density
and activity has been reported in the PBMC of end-stage
CHF patients compared to control subjects, in parallel with
significant increases of the plasma levels of TNFa and
soluble TNF receptors [80]. In these patients, upregulation
of A2A adenosine receptors in circulating cells progressive-
ly normalized after cardiac transplantation, in parallel with
the normalization of haemodynamic conditions and with
the reduction of plasma TNFα and soluble TNF receptors
towards normal values (ibidem; Fig. 4). These data indicate
a correlation between A2A receptors and cytokine produc-
tion in CHF and suggest that A2A receptors are upregulated
in an attempt to potentiate adenosine-mediated cytokine
inhibition. This hypothesis is consistent with the demon-
stration that both adenosine and adenosine-interfering
agents (i.e. dipyridamole and iodotubercidin, which inhibit
adenosine uptake and intracellular phosphorylation, respec-
tively) potently inhibit LPS-induced TNFa production and
release [81]. These effects could be blocked by A2 but not
by A1 or A3 receptor antagonists (ibidem). The specific
involvement of the A2A receptor in these actions was
confirmed in a later study. When stimulated ex vivo with
LPS, the PBMC from CHF patients produce greater
Fig. 4 Alterations of peripheral A2A receptors in CHF patients
progressively normalize after heart transplantation in parallel with the
normalization of haemodynamic conditions and of plasma cytokine
concentrations. In CHF patients, plasma levels of adenosine, TNFa
and its soluble receptor are elevated, whereas in peripheral circulating
cells A2A adenosine receptors are upregulated (see Varani et al. [80] for
more details). In these patients, the latter change mirrors the A2A
receptor changes occurring in the heart, the disease target organ. In a
cohort of these patients, A2A receptors in peripheral blood circulating
cells have been studied longitudinally as a function of time before and
after heart transplantation. The graph shows the longitudinal analysis
of A2A receptor density (Bmax) as determined with [
3H]-ZM 241385
binding in the lymphocytes of six patients, before and at different
times after heart transplantation (see inset for legend to individual
cases). Dotted horizontal line indicates the mean value of A2A receptor
density in control healthy subjects. Receptor density gradually returned
to normal values within 6 months after transplant. Similarly, the KD
value of [
3H]-ZM 241385 binding gradually and progressively
decreased to control values within the same time period (data not
shown). This trend was consistently evident for all evaluated patients
and was also detected in the neutrophils of the same subjects, showing
a progressive normalization of binding parameters to control values as
a function of time. In transplanted patients, plasma adenosine TNFa
and IL-6 levels also showed a trend to a decrease to values within 3-
6 months after transplant (see Capecchi et al. [82]). Therefore, the
cytokine milieu may regulate the function and the expression of A2A
adenosine receptors, thus contributing to establishing a negative
feedback mechanism against the progressive loop between pro-
inflammatory cytokines and heart failure (see also Capecchi et al.
[82]). Transplantation results in normalization of haemodynamics,
reduction of inflammation and normalization of the number and
function of A2A adenosine receptors. Modified from Varani et al. [80],
copyright 2003 with permission from The Federation of American
Society for Experimental Biology
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subjects [82]. However, despite increased TNFa produc-
tion, activation of A2A receptors (which are upregulated in
CHF, see above) by the selective A2A receptor agonist
CGS21680 induced a comparable inhibition of TNFa
release in both control and CHF patients. This effect was
blocked by ZM241385, a specific A2A antagonist. These
results suggest that upregulated A2A receptors in CHF
patients are efficiently coupled to their transduction system.
The inhibitory effect of A2A adenosine receptors on LPS-
induced TNFa production in monocytes could be attributed
to the increase of intracellular cAMP, which has been
shown to attenuate nuclear factor (NF)-κB-mediated tran-
scriptional activity (see also below). In line with previous
data suggesting the existence of a regulatory cross-talk
between TNFa and A2A adenosine receptor levels [83, 84],
the ex vivo incubation of PBMC from control subjects with
TNFa increased the expression of this adenosine receptor
subtype [82]. In contrast, under the same experimental
condition, TNFa did not further increase the expression of
the A2A receptor in the PBMC from CHF subjects,
suggesting that, in these patients, maximal induction had
already occurred in vivo.
On this basis, the following pathophysiological loop
acting in chronic heart failure may be suggested: in CHF
patients a high plasma level of endotoxin primes inflam-
matory cells to produce great amounts of cytokines; at the
same time, high concentrations of TNFa may induce
upregulation of the A2A adenosine receptor, in an attempt
to potentiate adenosine-mediated cytokine inhibition. Upre-
gulation of the A2A adenosine receptor in inflammatory
cells from CHF patients may thus represent an efficient,
although incomplete, mechanism of protection against
inappropriate cytokine production in the diseased heart.
These findings also suggest the A2A adenosine receptor as a
pharmacological target for novel therapeutic interventions
aimed at slowing down heart failure progression even after
activation of inflammatory cells has occurred.
Concluding remarks
The evidence reviewed above supports a crucial role for
specific adenosine receptors (mainly the A1 and A2A
receptor subtypes) in inhibition of pro-inflammatory cyto-
kine release, which has obvious important implications for
human pathophysiology. In principle, adenosine signalling
through these receptors is aimed at protecting tissues
against excessive inflammatory damage. Compelling evi-
dence points to a crucial role for the A2A adenosine receptor
in limitation and termination of inflammation. As reviewed
above and in Sitkovski et al. [9], no other factor could
compensate fully for the loss of A2A receptors on immune
cells, suggesting that this mechanism is non-redundant and
may have important implications in human diseases
characterized by excessive inflammation and/or overactiva-
tion of immune cells. In line with this hypothesis, in the
PBMC of patients with chronic heart failure, A2A receptors
were upregulated [80, 82], likely in an attempt to potentiate
adenosine inhibition of cytokine secretion. However, in the
end, this could not prevent heart disease progression,
suggesting that this mechanism is not able to fully protect
the heart against inappropriate cytokine production. Never-
theless, these data globally highlight the A2A receptor as an
interesting target for the development of new pharmaco-
logical strategies aimed at potentiating adenosine cytopro-
tection. In contrast, activation of the A2B receptor seems to
be responsible for pro-inflammatory actions, likely through
activation of Gq proteins, calcium mobilization and
stimulation of phospholipase C and mitogen-activated
protein kinase (reviewed in Linden [2]). As an example of
the deleterious consequences of this cascade, activation of
A2B receptors contributes to exacerbating histamine release
and disease progression in asthma and COPD (see above).
In line with this evidence, A2B blockers have been
hypothesized to be useful as anti-inflammatory agents.
The evidence summarized above also points to the
existence of a highly complex interplay among adenosine
receptors and cytokines. Not only can adenosine influence
cytokine expression and release, but cytokines can them-
selves modify adenosine receptor function by either
influencing their expression (e.g. [82]) or by inhibiting
adenosine receptor phosphorylation and downregulation
[68]. In some cases (for example in reactive astrogliosis)
this may contribute to developing cytoprotective mecha-
nisms in the first stages of the disease, but, when inflam-
mation becomes chronic, a dysregulation of these same
mechanisms may contribute to disease exacerbation. On this
basis, it is clear that a more in-depth knowledge of the
various regulatory pathways between adenosine and cyto-
kines might open up new therapeutic strategies to fully
exploit adenosine cytoprotection in acute and chronic
degenerative diseases.
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